Influence of luminal hepatocyte growth factor on small intestine mucosa in vivo

Yoshifumi Kato, Dahong Yu, Jeff R. Lukish, Marshall Z. Schwartz

Research output: Contribution to journalArticle

Abstract

In 1984, a growth factor was identified that stimulated hepatocyte DNA synthesis. This growth factor, referred to as hepatocyte growth factor (HGF), has been shown to enhance growth of intestinal epithelial cells in vitro. Recently, we reported that HGF can increase absorption and intestinal mass when given systemically in an in vivo model. This study was designed to examine if luminally administrated HGF can stimulate intestinal epithelial cell mass and function. Twenty-five young adult Sprague-Dawley rats had catheters inserted into the small intestine and connected to subcutaneously placed osmotic minipumps. The rats were divided into five groups (n = 5 for each group) based on the contents in the osmotic pump: group 1 received normal saline (control); groups 2, 3, 4, and 5 received HGF in increasing doses of 30, 75, 150, and 300 μg/kg/day, respectively. Following a 14 day infusion, [14C]galactose and [14C]glycine absorption was measured in 10- cm segments of mid-small intestine using an in vivo closed-recirculation technique. Mucosal DNA content and protein content of the same small bowel segment were determined for each group. HGF significantly increased galactose absorption at doses of 75 (P <0.01) and 150 (P <0.05) μg/kg/day and glycine absorption at doses of 30 (P <0.05) and 75 (P <0.01) μg/kg/day. HGF significantly increased DNA content (P <0.01) at each dose and protein content when given at 30 (P <0.01) and 75 (P <0.01) μg/kg/day. These data demonstrate that luminal administration of HGF can increase intestinal epithelial cell mass and function in vivo. HGF may be clinically useful in patients with inadequate intestinal function.

Original languageEnglish (US)
Pages (from-to)49-53
Number of pages5
JournalJournal of Surgical Research
Volume71
Issue number1
DOIs
StatePublished - Jul 15 1997
Externally publishedYes

Fingerprint

Hepatocyte Growth Factor
Small Intestine
Mucous Membrane
Epithelial Cells
Galactose
Glycine
DNA
Intercellular Signaling Peptides and Proteins
Intestinal Absorption
Sprague Dawley Rats
Young Adult
Hepatocytes
Proteins
Catheters
Growth

ASJC Scopus subject areas

  • Surgery

Cite this

Influence of luminal hepatocyte growth factor on small intestine mucosa in vivo. / Kato, Yoshifumi; Yu, Dahong; Lukish, Jeff R.; Schwartz, Marshall Z.

In: Journal of Surgical Research, Vol. 71, No. 1, 15.07.1997, p. 49-53.

Research output: Contribution to journalArticle

Kato, Yoshifumi ; Yu, Dahong ; Lukish, Jeff R. ; Schwartz, Marshall Z. / Influence of luminal hepatocyte growth factor on small intestine mucosa in vivo. In: Journal of Surgical Research. 1997 ; Vol. 71, No. 1. pp. 49-53.
@article{a59e42c057d44f46839f2d457d375c9e,
title = "Influence of luminal hepatocyte growth factor on small intestine mucosa in vivo",
abstract = "In 1984, a growth factor was identified that stimulated hepatocyte DNA synthesis. This growth factor, referred to as hepatocyte growth factor (HGF), has been shown to enhance growth of intestinal epithelial cells in vitro. Recently, we reported that HGF can increase absorption and intestinal mass when given systemically in an in vivo model. This study was designed to examine if luminally administrated HGF can stimulate intestinal epithelial cell mass and function. Twenty-five young adult Sprague-Dawley rats had catheters inserted into the small intestine and connected to subcutaneously placed osmotic minipumps. The rats were divided into five groups (n = 5 for each group) based on the contents in the osmotic pump: group 1 received normal saline (control); groups 2, 3, 4, and 5 received HGF in increasing doses of 30, 75, 150, and 300 μg/kg/day, respectively. Following a 14 day infusion, [14C]galactose and [14C]glycine absorption was measured in 10- cm segments of mid-small intestine using an in vivo closed-recirculation technique. Mucosal DNA content and protein content of the same small bowel segment were determined for each group. HGF significantly increased galactose absorption at doses of 75 (P <0.01) and 150 (P <0.05) μg/kg/day and glycine absorption at doses of 30 (P <0.05) and 75 (P <0.01) μg/kg/day. HGF significantly increased DNA content (P <0.01) at each dose and protein content when given at 30 (P <0.01) and 75 (P <0.01) μg/kg/day. These data demonstrate that luminal administration of HGF can increase intestinal epithelial cell mass and function in vivo. HGF may be clinically useful in patients with inadequate intestinal function.",
author = "Yoshifumi Kato and Dahong Yu and Lukish, {Jeff R.} and Schwartz, {Marshall Z.}",
year = "1997",
month = "7",
day = "15",
doi = "10.1006/jsre.1997.5136",
language = "English (US)",
volume = "71",
pages = "49--53",
journal = "Journal of Surgical Research",
issn = "0022-4804",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - Influence of luminal hepatocyte growth factor on small intestine mucosa in vivo

AU - Kato, Yoshifumi

AU - Yu, Dahong

AU - Lukish, Jeff R.

AU - Schwartz, Marshall Z.

PY - 1997/7/15

Y1 - 1997/7/15

N2 - In 1984, a growth factor was identified that stimulated hepatocyte DNA synthesis. This growth factor, referred to as hepatocyte growth factor (HGF), has been shown to enhance growth of intestinal epithelial cells in vitro. Recently, we reported that HGF can increase absorption and intestinal mass when given systemically in an in vivo model. This study was designed to examine if luminally administrated HGF can stimulate intestinal epithelial cell mass and function. Twenty-five young adult Sprague-Dawley rats had catheters inserted into the small intestine and connected to subcutaneously placed osmotic minipumps. The rats were divided into five groups (n = 5 for each group) based on the contents in the osmotic pump: group 1 received normal saline (control); groups 2, 3, 4, and 5 received HGF in increasing doses of 30, 75, 150, and 300 μg/kg/day, respectively. Following a 14 day infusion, [14C]galactose and [14C]glycine absorption was measured in 10- cm segments of mid-small intestine using an in vivo closed-recirculation technique. Mucosal DNA content and protein content of the same small bowel segment were determined for each group. HGF significantly increased galactose absorption at doses of 75 (P <0.01) and 150 (P <0.05) μg/kg/day and glycine absorption at doses of 30 (P <0.05) and 75 (P <0.01) μg/kg/day. HGF significantly increased DNA content (P <0.01) at each dose and protein content when given at 30 (P <0.01) and 75 (P <0.01) μg/kg/day. These data demonstrate that luminal administration of HGF can increase intestinal epithelial cell mass and function in vivo. HGF may be clinically useful in patients with inadequate intestinal function.

AB - In 1984, a growth factor was identified that stimulated hepatocyte DNA synthesis. This growth factor, referred to as hepatocyte growth factor (HGF), has been shown to enhance growth of intestinal epithelial cells in vitro. Recently, we reported that HGF can increase absorption and intestinal mass when given systemically in an in vivo model. This study was designed to examine if luminally administrated HGF can stimulate intestinal epithelial cell mass and function. Twenty-five young adult Sprague-Dawley rats had catheters inserted into the small intestine and connected to subcutaneously placed osmotic minipumps. The rats were divided into five groups (n = 5 for each group) based on the contents in the osmotic pump: group 1 received normal saline (control); groups 2, 3, 4, and 5 received HGF in increasing doses of 30, 75, 150, and 300 μg/kg/day, respectively. Following a 14 day infusion, [14C]galactose and [14C]glycine absorption was measured in 10- cm segments of mid-small intestine using an in vivo closed-recirculation technique. Mucosal DNA content and protein content of the same small bowel segment were determined for each group. HGF significantly increased galactose absorption at doses of 75 (P <0.01) and 150 (P <0.05) μg/kg/day and glycine absorption at doses of 30 (P <0.05) and 75 (P <0.01) μg/kg/day. HGF significantly increased DNA content (P <0.01) at each dose and protein content when given at 30 (P <0.01) and 75 (P <0.01) μg/kg/day. These data demonstrate that luminal administration of HGF can increase intestinal epithelial cell mass and function in vivo. HGF may be clinically useful in patients with inadequate intestinal function.

UR - http://www.scopus.com/inward/record.url?scp=0031571111&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031571111&partnerID=8YFLogxK

U2 - 10.1006/jsre.1997.5136

DO - 10.1006/jsre.1997.5136

M3 - Article

C2 - 9271277

AN - SCOPUS:0031571111

VL - 71

SP - 49

EP - 53

JO - Journal of Surgical Research

JF - Journal of Surgical Research

SN - 0022-4804

IS - 1

ER -